We provide an overview of the epidemiology and clinical course of mucormycosis in the coronavirus disease (COVID-19) pandemic era. We conducted a retrospective chart review of 178 patients with clinical or diagnostic, endoscopically or histopathologically confirmed rhino-sino-orbital or cerebral mucormycosis after COVID-19 treatment during the second wave of COVID-19 in Pune, India. Median time to symptom onset from COVID-19 detection was 28 days. Moderate or severe COVID-19 was seen in 73% of patients and diabetes in 74.2%. A total of 52.8% received steroids. Eschar over or inside the nose was seen in 75%, but baseline clinical and laboratory parameters were mostly unremarkable. Bone penetration was present in ≈90% of cases, 30% had soft-tissue swelling of the pterygopalatine fossa and 7% had cavernous sinus thrombosis, and 60% had multifocal mucormycosis. Of the 178 study cases, 151 (85%) underwent surgical debridement. Twenty-six (15%) died, and 16 (62%) of those had multifocal mucormycosis.

我们概述了冠状病毒病 (COVID-19) 大流行时代毛霉菌病的流行病学和临床病程。我们对印度浦那第二波 COVID-19 期间接受 COVID-19 治疗后经临床或诊断、内窥镜或组织病理学确诊为鼻窦或脑毛霉菌病的 178 名患者进行了回顾性图表审查。从检测到 COVID-19 到出现症状的中位时间为 28 天。73% 的患者患有中度或重度 COVID-19，74.2% 的患者患有糖尿病。总共 52.8% 的人接受了类固醇治疗。75% 的人在鼻子上方或内部可见焦痂，但基线临床和实验室参数大多不显着。约90%的病例存在骨穿透，30%有翼腭窝软组织肿胀，7%有海绵窦血栓，60%有多灶性毛霉菌病。在 178 个研究病例中，151 个（85%）接受了手术清创术。26 人 (15%) 死亡，其中 16 人 (62%) 患有多灶性毛霉菌病。